New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 4, 2001, Pages 27-29

  Ettinger, David S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL TIME;

EID: 0034909054     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90075-2     Document Type: Short Survey

References (9)

1. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: An Eastern Cooperative Oncology Group Study
2. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer. A study of the North Central Cancer Treatment Group
3. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial
4. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial
5. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer
6. A phase II study of CPT-11, a camptothecin derivative in patients with primary lung cancer
7. Phase II study of navelbine (NVB) in small cell lung cancer (SCLC)
8. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
9. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline in previously untreated patients with extensive stage small cell cancer (ESSCLC): A West Japan Lung Cancer Group Trial